Looking back over the previous Q filings, I would agree that the numbers change (in Q2, they said they would need $15M over the next 12 months), and that verbiage looks standardized.
The questions remain:
1). Does the new Aspire agreement allow purchase of shares from IPIX at a 29% discount to the 52-week low (currently at .325) ?
2). If so - what will happen to the share price if they try to raise $9M over the next 12 months, with the share price where it is?
Look at the numbers - from 9/6/17 to 3/31/18 (over 6 months) they raised $5.7M with 8.7M shares, for an average price of .655 / share. From 4/1/18 to 5/9/18 ( a little over 1 month) they raised $2.0M with 8M shares, for an average price of .25 / share. Does that look right?
Also - I don't remember seeing much about this side venture in the filings, previously:
What exactly is Innovative Medical Research Inc. pursuing, on the premises of Innovation Pharmaceuticals, Inc?
The questions remain:
1). Does the new Aspire agreement allow purchase of shares from IPIX at a 29% discount to the 52-week low (currently at .325) ?
2). If so - what will happen to the share price if they try to raise $9M over the next 12 months, with the share price where it is?
Look at the numbers - from 9/6/17 to 3/31/18 (over 6 months) they raised $5.7M with 8.7M shares, for an average price of .655 / share. From 4/1/18 to 5/9/18 ( a little over 1 month) they raised $2.0M with 8M shares, for an average price of .25 / share. Does that look right?
Also - I don't remember seeing much about this side venture in the filings, previously:
Quote:In addition, Innovative Medical Research Inc., (“Innovative Medical”) a company owned by Mr. Ehrlich and Dr. Menon, officers of the Company, has co-signed the lease and rents approximately 200 square feet of office space, the space previously used by the Company and pays the Company $900 per month, the same amount the Company previously paid KARD. Innovative Medical paid total rent of approximately $3,000 and $9,000 to the Company for both of the three months and nine months ended March 31, 2018 and 2017 and the rental payment was offset with the accrued rent owed to KARD.
What exactly is Innovative Medical Research Inc. pursuing, on the premises of Innovation Pharmaceuticals, Inc?
